Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.49 |
| ▸ | NT5E | P21589 | 4/20 | 0.45 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.44 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19765675 | 1.00 | P2RY1 (0.49) | P2RY1P2RY2NT5EGPR17RNASEL | |
| SCHEMBL19765678 | 0.99 | P2RY1 (0.51) | P2RY1P2RY2NT5EGPR17RNASEL | |
| SCHEMBL19765696 | 0.99 | P2RY1 (0.51) | P2RY1P2RY2NT5EGPR17RNASEL | |
| SCHEMBL19765674 | 0.94 | P2RY1 (0.52) | P2RY1P2RY2NT5E | |
| SCHEMBL19765664 | 0.94 | P2RY1 (0.52) | P2RY1P2RY2NT5E | |
| SCHEMBL19765779 | 0.87 | RNASEL (0.42) | P2RY1P2RY2NT5ERNASEL | |
| SCHEMBL19765803 | 0.87 | RNASEL (0.43) | P2RY1P2RY2NT5EGPR17RNASEL | |
| SCHEMBL16377085 | 0.85 | P2RY1 (0.46) | P2RY1P2RY2NT5EGPR17 | |
| SCHEMBL20724577 | 0.83 | ADORA3 (0.43) | P2RY1NT5E | |
| SCHEMBL16367960 | 0.82 | IMPDH2 (0.43) | P2RY1P2RY2RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009836-A1 | BETA-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINENUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS | Atea Pharmaceuticals, Inc. (US) | 2018-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009836-A1 | BETA-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINENUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS | MTAP, NSUN2, TPMT | P2RY1 264/4885P2RY2 197/4885NT5E 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.